Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
UCB Japan Co. Ltd.
Objectives of the Second Period: To provide the Levetiracetam treatment to subjects who are judged by the investigators to benefit from the long-term treatment and who are willing to continuously receive this drug. To continuously evaluate the safety of the Levetiracetam long-term administration at doses ranging from 20 mg/kg/day or 1000 mg/day to 60 mg/kg/day or 3000 mg/day in subjects who completed the First Period of this study.
Age
4–16
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
The patient has partial Epilepsy and the diagnosis must be confirmed in the last 6 months
The patients must be on a stable 1 or 2 anti-epileptic drug(s) treatment during the 4 weeks prior to Baseline and must have at least 8 partial seizures during the 8-week prospective Baseline Period
Patient at the age of 4 to 16 years, and at the body weight of 11 to 82 kg
You may not be if
The patient has a treatable seizure etiology
The patient has Epilepsy secondary to a progressive cerebral disease or any other progressively neurodegenerative disease, including Rasmussen and Landau-Kleffner diseases
The patient has a history of status Epilepticus during the 3 months prior to Visit 1
The patient has a past and present history of pseudo seizures
The patient has a current diagnosis of Lennox-Gastaut syndrome
Clareo Health | An Open Label Study of Levetiracetam in Japanese Pediatric Patients With Partial Seizures
